Polymorphisms of Toll-like receptor-4 and CD14 in systemic lupus erythematosus and rheumatoid arthritis

Biomarker Research

Tarak Dhaouadi³  Imen Sfar³  Youssra Haouami³  Leila Abdelmoula¹  Sami Turki⁴  Lamia Ben Hassine²  Rafik Zouari¹  Adel Khedher⁴  Narjess Khalfallah²  Taieb Ben Abdallah³  Yousr Gorgi³ 

[1] Rheumatology Department Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia

[2] Internal Medicine Department B Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia

[3] Laboratory of Research in Immunology of Renal Transplantation and Immunopathology (LR03SP01) Charles Nicolle Hospital, Tunis El Manar University, Bd 9 Avril, 1006 Bab Saadoun, Tunis, Tunisia

[4] Internal Medicine Department A Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia

关键词: Rheumatoid arthritis;    Systemic lupus erythematosus;    CD14;    TLR4;    Polymorphisms;   

Others  :  791965
DOI  :  10.1186/2050-7771-1-20

 received in 2013-03-11, accepted in 2013-05-08,  发布年份 2013

【 摘 要 】

Background

Toll-like receptor 4 (TLR4) and its co-receptor CD14 play a major role in innate immunity by recognizing PAMPs and signal the activation of adaptive responses. These receptors can recognize endogenous ligands mainly auto-antigens. In addition, TLR4 (Asp299Gly) and CD14 (C/T -159) polymorphisms (SNPs) may modify qualitatively and/or quantitatively their expression. Therefore, they could be implied in autoimmune diseases and can influence both susceptibility and severity of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Patients and methods

TLR4 (Asp299Gly) and CD14 (C/T -159) SNPs were genotyped using polymerase chain reaction (PCR)-RFLP in 127 SLE patients, 100 RA patients, and 114 healthy controls matched in age and gender.

Results

CD14*T allele was significantly more frequent in SLE patients (0.456) comparatively to controls (0.355), p = 0.02 OR (95% CI) = 1.53 [1.04-2.24]. In RA patients, the higher frequency of CD14*T allele (0.405) failed to reach significance, p = 0.28. Investigation of the TLR4 (Asp299Gly) SNP showed no significant association neither with SLE nor with RA.

Analysis of these SNPs according to clinical and biological features showed a significant higher frequency of arthritis in SLE patients carrying CD14*T/T genotype (92%) comparatively to those with C/C and C/T genotypes (72.5%), p = 0.04. Moreover, SLE patients carrying CD14*T/T/TLR4*A/A haplotype had significantly more arthritis (91.3%) than the rest of SLE group (73%), p = 0,044 and confirmed by multivariable analysis after adjustment according to age and gender, p = 0.01.

Conclusion

The CD14 (-159)*T allele seems to be associated with susceptibility to SLE and arthritis occurrence.

【 授权许可】

   
2013 Dhaouadi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kaplan MJ: Apoptosis in systemic lupus erythematosus. Clin Immunol 2004, 112:210-218.
• [2]Schedel J, Gay RE, Kuenzler P, Seemayer C, Simmen B, Michel BA, Gay S: FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum 2002, 46:1512-1518.
• [3]Liu H, Pope RM: The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 2003, 3:317-322.
• [4]Richez C, Blanco P, Rifkin I, Moreau JF, Schaeverbeke T: Role for toll-like receptors in autoimmune disease: The example of systemic lupus erythematosus. Joint Bone Spine 2011, 78:124-130.
• [5]Okayama N, Fujimura K, Suehiro Y, Hamanaka Y, Fujiwara M, Matsubara T, Maekawa T, Hazama S, Oka M, Nohara H, Kayano K, Okita K, Hinoda Y: Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal 2002, 16(1):56-58.
• [6]Schmitt C, Humeny A, Becker CM, Brune K, Pahl A: Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem 2002, 48(10):1661-1667.
• [7]LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, Vercelli D: A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2012, 167:5838-5844.
• [8]Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
• [9]Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
• [10]Miller SA, Dykes DD, Polesky HG: A sampling salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1218.
• [11]Hang L, Slack JH, Amundson C, Izui S, Theofilopoulos AN, Dixon FJ: Induction of murine autoimmune disease by chronic polyclonal B cell activation. J Exp Med 1983, 157:874-883.
• [12]Liu B, Yang Y, Dai J, Medzhitov R, Freudenberg MA, Zhang PL, Li Z: TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 2006, 177:6880-6888.
• [13]Sanchez E, Orozco G, López-Nevot MÁ, Jiménez-Alonso J, Martín J: Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2004, 63:54-57.
• [14]Kang ES, Lee J: Genotypic analysis of Asp299Gly and Thr399Ile polymorphism of toll-like receptor 4 in systemic autoimmune diseases of Korean population. Rheumatol Int 2007, 27:887-889.
• [15]Lin YC, Chang YM, Yu JM, Yen JH, Chang JG, Hu CJ: Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis 2005, 180(2):305-309.
• [16]Kilding R, Akil M, Till S, Amos R, Winfield J, Iles MM, Wilson AG: A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:340-342.
• [17]Jean O, Petit-Teixeira E, Kirsten H, Ahnert P, Semerano L, Pierlot C, Cornelis F, Boissier MC, Falgarone G: No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R5. BioMed Central Full Text
• [18]Emonts M, Hazes MJMW, Houwing-Duistermaat JJ, Van Der Gaast-De Jongh CE, De Vogel L, Han HKH, Wouters JMGW, Laman JD, Dolhain RJEM: Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: a case control study. BMC Med Genet 2011, 12:36.
• [19]Radstake TRDJ, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P, Joosten LAB, Van Riel PLCM, Van Den Berg WB: The toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum 2004, 50(3):999-1001.
• [20]Vogel SN, Awomoyi AA, Rallabhandi P, Medvedev AE: Mutation in TLR4 signaling that lead to increased susceptibility to infection in humans: an overview. J Endotoxin Res 2005, 11(6):333-339.
• [21]Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztein MB, Boukhvalova MS, Hemming VG, Blanco JCG, Vogel SN: Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 2007, 179:3171-3177.
• [22]Yuan FF, Marks K, Wong M, Watson S, De Leon E, McIntyre PB, Sullivan JS: Clinical relevance of TLR2, TLR4, CD14 and FcγRIIA gene polymorphisms in Streptococcus pneumonia infection. Immunol Cell Biol 2008, 86:268-270.
• [23]Gasparoto TH, Tessaroli V, Garlet TP, Torres SA, Garlet GP, Da Silva JS, Campanelli AP: Absence of functional TLR4 impairs response of macrophages after Candida albicans infection. Med Mycol 2010, 48(8):1009-1017.
• [24]Barber RC, Aragaki CC, Rivera-Chavez FA, Purdue GF, Hunt JL, Horton JW: TLR4 and TNF-α polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet 2004, 41:808-813.
• [25]Das B, Panda A, Tripathy R: Effect of TLR4 (Asp299Gly), TLR9 (T1237C) and CD14 (C159T) gene polymorphism and susceptibility to SLE. Indian J Rheumatol 2011, 6(3):S4.
• [26]Nockher WA, Wigand R, Schoeppe W, Scherberich JE: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 1994, 96:15-19.
• [27]Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dörner T: Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000, 9(8):614-621.
• [28]Sümegi A, Antal-Szalmás P, Aleksza M, Kovács I, Sipka S, Zeher M, Kiss E, Szegedi G: Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus. Clin Immunol 2005, 117(3):271-279.
• [29]De La Fontaine L, Schwarz M, Plischke H, Kleindienst N, Gruber R: Lack of association of the CD14/C-159T polymorphism with susceptibility and serological activity parameters of rheumatoid arthritis. Scand J Rheumatol 2006, 35:20-22.
• [30]Mikuls TR, LeVan TD, Sayles H, Yu F, Caplan L, Cannon GW, Kerr GS, Reimold AM, Johnson DS, Thiele GM: Soluble CD14 and CD14 polymorphisms in rheumatoid arthritis. J Rheumatol 2011, 38(12):2509-2516.